
## CLAIMS

1. A compound of Formula (I):




(I)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently nitrogen-containing heterocyclyl or nitrogen-containing heteroaryl, each of which is optionally substituted with one or more $R^1$, wherein at least one of A and B is said heteroaryl and is bicyclic;

$L^1$ and $L^2$ are each independently absent or -$N(R^3)$-;

X is N or C;

Y is N, $N(R^{5a})$, or $C(R^{5b})$, wherein the dashed lines representing bonds in the ring comprising X and Y may be single or double bonds as valency permits;

Z is N or $C(R^6)$;

each $R^1$ is independently hydrogen, $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkenylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, $–OR^A$, $–NR^BR^C$, $–NR^BC(O)R^D$, $–NO_2$, $–C(O)NR^BR^C$, $–C(O)R^D$, $–C(O)OR^D$, or $–S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^7$; or

two $R^1$ groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^7$;

$R^2$ is absent, hydrogen, or $C_1$-$C_6$-alkyl;

each $R^3$ is independently hydrogen, $C_1$-$C_6$-alkyl, or $C_1$-$C_6$-haloalkyl;

$R^{5a}$ is hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl;

$R^{5b}$ is hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, halo, or $–OR^A$;

$R^6$ is hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, or halo;

each $R^7$ is independently $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, $–OR^A$, $–NR^BR^C$, $–NR^BC(O)R^D$, $–NO_2$, $–C(O)NR^BR^C$, $–C(O)R^D$, $–C(O)OR^D$, or $–S(O)_xR^D$, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^8$;

each $R^8$ is independently $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $–OR^A$;

each $R^A$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, $–C(O)R^D$, or $–S(O)_xR^D$;




each $R^B$ and $R^C$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ heteroalkyl, cycloalkyl, heterocyclyl, $–OR^A$; or

$R^B$ and $R^C$ together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more $R^9$;





each $R^D$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_1$-$C_6$ heteroalkyl, $C_1$-$C_6$ haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, or $C_1$-$C_6$ alkylene-heteroaryl;

each $R^9$ is independently $C_1$-$C_6$-alkyl or halo; and




x is 0, 1, or 2.


2. The compound of claim 1, wherein A is selected from , , and , wherein $R^1$ is as described in claim 1.



3. The compound of any one of claims 1-2, wherein A is selected from

, ,  and , wherein $R^1$ is as described in claim 1.

4. The compound of any one of claims 1-3, wherein B selected from

, , and , wherein $R^1$ is as described in claim 1.

5. The compound of any one of claims 1-3, wherein B is selected from, ,


, , wherein $R^1$ is as described in claim 1.

6. The compound of any one of the preceding claims, wherein each of $L^1$ and $L^2$ is independently absent.

7. The compound of any one of the preceding claims, wherein Y is $N(R^{5a})$ or $C(R^{5b})$.

8. The compound of any one of the preceding claims, wherein $R^2$ is absent.


9. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-a):



(I-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, X, Y, Z, $R^2$, and subvariables thereof are as defined in claim 1.


10. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-b):



(I-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, X, Y, $R^2$, and subvariables thereof are as defined in claim 1.


11. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-c):



(I-c),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, Z, and subvariables thereof are as defined in claim 1.

12. The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-d):




(I-d),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, Z, and subvariables thereof are as defined in claim 1.

13. The compound of any one of the preceding claims, wherein the compound of Formula (I) is selected from any one of the compounds shown in Table 1 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

14. A compound of Formula (II):




(II)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A and B are each independently nitrogen-containing heterocyclyl or nitrogen-containing heteroaryl, each of which is optionally substituted with one or more $R^1$, wherein at least one of A and B is said heteroaryl and is bicyclic;

$L^1$ and $L^2$ are each independently absent, or -N($R^3$)-;

Y is N or C, wherein the dashed lines representing bonds in the ring comprising Y may be single or double bonds as valency permits;

Z is N or C($R^6$);

each $R^1$ is independently hydrogen, $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkenylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –$OR^A$, –$NR^BR^C$, –$NR^BC(O)R^D$, –$NO_2$, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, or –$S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^8$; or

two $R^1$ groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^8$;

$R^2$ is absent, hydrogen, or $C_1$-$C_6$-alkyl;

each $R^3$ is independently hydrogen, $C_1$-$C_6$-alkyl, or $C_1$-$C_6$-haloalkyl;

$R^6$ is hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, or halo;

$R^7$ is hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, halo, or $–OR^A$;

each $R^8$ is independently $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, $–OR^A$, $–NR^BR^C$, $–NR^BC(O)R^D$, $–NO_2$, $–C(O)NR^BR^C$, $–C(O)R^D$, $–C(O)OR^D$, or $–S(O)_xR^D$, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^9$;

each $R^9$ is independently $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $–OR^A$;

each $R^A$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, $–C(O)R^D$, or $–S(O)_xR^D$;



each $R^B$ and $R^C$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ heteroalkyl, cycloalkyl, heterocyclyl, $–OR^A$; or





$R^B$ and $R^C$ together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more $R^{10}$;










each $R^D$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_1$-$C_6$ heteroalkyl, $C_1$-$C_6$ haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, or $C_1$-$C_6$ alkylene-heteroaryl;




each $R^{10}$ is independently $C_1$-$C_6$-alkyl or halo; and

x is 0, 1, or 2.

15. The compound of claim 14, wherein A is selected from,  and , wherein $R^1$ is as described in claim 14.

16. The compound of claim 14, wherein A is selected from , ,  and . , wherein $R^1$ is as described in claim 14.


17. The compound of any one of claims 14-16, wherein B selected from selected from , , , , , , , , and . wherein $R^1$ is as described in claim 14.

18. The compound of any one of claims 14-16, wherein B is selected from , , and , wherein $R^1$ is as described in claim 14.

19. The compound of any one of claims 14-18, wherein each of $L^1$ and $L^2$ is independently absent.

20. The compound of any one of claims 14-19, wherein Y is N.


21. The compound of any one of claims 14-20, wherein the compound of Formula (II) is a compound of Formula (II-a):



(II-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, Z, Y, $R^2$, $R^7$, and subvariables thereof are as defined in claim 14.


22. The compound of any one of claims 14-21, wherein the compound of Formula (II) is a compound of Formula (II-b):



(II-b)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, Y, $R^2$, $R^7$, and subvariables thereof are as defined in claim 14.


23. The compound of any one of claims 14-22, wherein the compound of Formula (II) is a compound of Formula (II-c):



(II-c)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, $R^7$, and subvariables thereof are as defined in claim 14.

24. The compound of any one of claims 14-23, wherein the compound of Formula (II) is a compound of Formula (II-d):



(II-d),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, $L^1$, Z, $R^7$, and subvariables thereof are as defined in claim 14.

25. The compound of any one of claims 14-24, wherein the compound of Formula (II) is selected from any one of the compounds shown in Table 2 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

26. A pharmaceutical composition comprising a compound of any one of claims 1-25 and a pharmaceutically acceptable excipient.

27. The compound of any one of claims 1-25 or the pharmaceutical composition of claim 26, wherein the compound alters, binds to, or stabilizes a target nucleic acid.

28. The compound of any one of claims 1-25 or the pharmaceutical composition of claim 26, wherein the compound increases or decreases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more.

29. A method of modulating splicing of a nucleic acid comprising contacting the nucleic acid with a compound of Formula (I) or (II), according to any one of claims 1-25 or the pharmaceutical composition of claim 26.

30. The method of claim 29, wherein the compound increases or decreases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more.

31. A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid, and a compound of Formula (I) or Formula (II):

comprising contacting the nucleic acid with a compound of Formula (I) or (II), according to any one of claims 1-25 or the pharmaceutical composition of claim 26.

32. The method of claim 31, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I) or (II).

33. A method of altering the conformation of a nucleic acid comprising contacting the nucleic acid with a compound of Formula (I) or (II), according to any one of claims 1-25 or the pharmaceutical composition of claim 26.

34. The method of claim 33, wherein the altering comprises forming, stabilizing, or reducing a bulge in the nucleic acid.

35. The method of any one of claims 33-34, wherein the nucleic acid comprises a splice site.

36. A composition for use in treating a disease or disorder in a subject comprising a compound of Formula (I) or (II) to be administered, according to any one of claims 1-25 or the pharmaceutical composition of claim 26.

37. The composition for use of claim 36, wherein the disease or disorder comprises a proliferative disease.

38. The composition for use of claim 36, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

39. The composition for use of claim 36, wherein the disease or disorder comprises neurological disease or disorder.

40. The composition for use of claim 36, wherein the disease or disorder comprises Huntington's disease.

41. A use of a compound of Formula (I) or (II), according to any one of claims 1-25 or the pharmaceutical composition of claim 26 in the manufacture of a medicament for treating a disease or disorder selected from a proliferative disease, a neurological disease or disorder, an autoimmune disease or disorder, an immunodeficiency disease or disorder, a lysosomal storage disease or disorder, a cardiovascular disease or disorder, a metabolic disease or disorder, a respiratory disease or disorder, a renal disease or disorder, or an infectious disease.

42. The use of claim 41, wherein the disease or disorder comprises a proliferative disease.

43. The use of claim 41, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

44. The use of claim 41, wherein the disease or disorder comprises neurological disease or disorder.

45. The use of claim 41, wherein the disease or disorder comprises Huntington's disease.